Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

被引：0
|
作者：
de Jesus, Cabrera-Lopez Teresita [1 ]
Edgar, Perez-Barragan [2 ]
Ruben, Nava-Campos Carlos [1 ]
Marla, Toiber-Rodriguez [3 ]
Carlos, Rodriguez-Aldama Juan [2 ]
Adrian, Cruz-Flores Raul [4 ]
Andrea, Gonzalez-Rodriguez [5 ]
机构：
[1] Clin Especializada Condesa Iztapalapa, Dept Gynecol & Care Victims Sexual Assault, Mexico City, Mexico
[2] Clin Especializada Condesa Iztapalapa, Dept Infect Dis, Combate Celaya 352, Mexico City 09730, Mexico
[3] Clin Especializada Condesa Iztapalapa, Dept Mental Hlth, Mexico City, Mexico
[4] Clin Especializada Condesa Iztapalapa, Dept Epidemiol, Mexico City, Mexico
[5] Clin Especializada Condesa, Mexico City, Mexico
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 08期
关键词：
bictegravir/emtricitabine/tenofovir alafenamide; HIV; INSTI; post-exposure prophylaxis; sexual assault; HIV; HEALTH; RECOMMENDATIONS; EXPOSURE;
D O I：
10.1093/ofid/ofae436
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Effectiveness of Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in treatment-experienced people with HIV using real-world data: A systematic review and meta-analysis
    Chivite, I.
    Berrocal, L.
    De lazzari, E.
    Navadeh, S.
    Lluis, C.
    Inciarte, A.
    De la Mora, L.
    Gonzalez-Cordon, A.
    Martinez-Rebollar, M.
    Laguno, M.
    Torres, B.
    Blanco, J. L.
    Martinez, E.
    Mallolas, J.
    Ambrosioni, J.
    HIV MEDICINE, 2023, 24 : 70 - 71
  • [42] Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis
    Chivite, Ivan
    Berrocal, Leire
    de Lazzari, Elisa
    Navadeh, Soodabeh
    Lluis-Ganella, Carla
    Inciarte, Alexy
    de la Mora, Lorena
    Gonzalez-Cordon, Ana
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    Torres, Berta
    Blanco, Jose Luis
    Martinez, Esteban
    Mallolas, Josep
    Ambrosioni, Juan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 1775 - 1783
  • [43] Patient-reported outcomes among people living with HIV on bictegravir/ emtricitabine/tenofovir alafenamide fixed-dose combination: Real-world data from Latin America
    Cecchini, D. M.
    Seleme, S.
    Mingrone, M. V.
    Diana Menendez, S.
    Mauas, R.
    Bottaro, E.
    Cassetti, I.
    HIV MEDICINE, 2023, 24 : 414 - 414
  • [44] Real-world effects of treatment with emtricitabine/tenofovir alafenamide- versus emtricitabine/tenofovir disoproxil fumarate-based regimens in people living with HIV in a clinical cohort in Germany
    Rieke, A.
    Jessen, H.
    Pauli, R.
    Waizmann, M.
    Heuchel, T.
    Postel, N.
    Lymperopoulou, C.
    Faghmous, I.
    Diaz-Cuervo, H.
    Ramroth, H.
    Stellbrink, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [45] Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV
    Lee, Shu-Yuan
    Lin, Yi-Chun
    Chen, Cheng-Pin
    Cheng, Shu-Hsing
    Chang, Shu-Ying
    Ku, Shin-Yen
    Cheng, Chien-Yu
    PLOS ONE, 2024, 19 (11):
  • [46] Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
    Chen, En-Qiang
    Li, Lan-Qing
    Zhou, Jing
    Li, Yu-Jing
    Wang, Fa-Da
    Zhang, Dong-Mei
    Wang, Meng-Lan
    GUT, 2023, 72 (SUPPL_1) : A157 - A159
  • [47] Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
    Li, Lanqing
    Zhou, Jing
    Li, Yujing
    Wang, Fada
    Zhang, Dongmei
    Wang, Menglan
    Tao, Yachao
    Chen, Enqiang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] Clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide-real-world data from German IQVIA prescription database
    Umland, Tim
    Stellbrink, Hans-Juergen
    Calvo, Marta
    Zahn, Astrid
    INFECTION, 2021, 49 (SUPPL 1) : S22 - S23
  • [49] Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence
    Boffito, Marta
    Brunetta, Jason
    Levy, Itzchak
    Yang, Chia-Jui
    Portilla, Joaquin
    De Barra, Eoghan
    Vogelmann, Roger
    Endo, Tomoyuki
    Robineau, Olivier
    Sarmati, Loredana
    Thorpe, David
    Marongiu, Andrea
    Cassidy, Tali
    van Welzen, Berend
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 79 - 82
  • [50] Patient-reported outcome measures at 12 months in a real-world cohort of people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
    Brunetta, Jason
    Monforte, Antonella
    van Welzen, Berend
    Milinkovic, Ana
    Marongiu, Andrea
    Heinzkill, Marion
    Thorpe, David
    Cornejo, Almudena Torres
    Antela, Antonio
    HIV MEDICINE, 2022, 23 : 76 - 76
12345